Revenue

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Facing a fiscal crunch, San Diego County's move to a cloud-based budget system offers a model for data-driven efficiency and public service reform.

JFB Construction's CEO just invested $100k of his own money in company stock. We dive into the projects and market trends fueling this bold move.

Spectral Capital projects massive growth via acquisitions and quantum tech, but its ambitious NASDAQ plan faces significant financial and execution hurdles.

PERIOD. appoints Jennifer Herrera as its new ED. How will her background in national advocacy and grassroots organizing reshape the fight for menstrual equity?

Animal health giant Elanco is restructuring its global footprint, betting its future on a U.S.-centric innovation pipeline and blockbuster pet health drugs.

OutSystems' #1 G2 ranking isn't just an award; it signals a seismic shift where AI-powered low-code and user satisfaction are the new currencies.

Groundbreaking lymphoma data and a strategic acquisition position Natera to dominate the liquid biopsy market, challenging old standards and creating new value.

Vancouver's SimplyAsk.ai and Mexican telecom giant Axtel partner to tackle AI's high failure rate, aiming to unlock a multi-billion dollar market.

TransAlta is converting a massive coal plant to natural gas, a pragmatic yet controversial move in the push for a cleaner, reliable energy future.

Beyond the award, Pariveda's use of generative AI to modernize legacy systems reveals a powerful new playbook for enterprise transformation and value.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

The space tourism pioneer is restructuring its debt, buying precious time for its next-gen fleet but at a steep cost for shareholders and future finances.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

A landmark private equity deal in Europe's produce sector is about more than money; it's a strategic move to build a resilient food supply chain.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

How the world's largest Catholic media network leveraged its global infrastructure to turn a grassroots prayer event into a worldwide phenomenon.